EP2276502A4 - Compositions for the prevention and treatment of neuroinjury and methods of use thereof - Google Patents
Compositions for the prevention and treatment of neuroinjury and methods of use thereofInfo
- Publication number
- EP2276502A4 EP2276502A4 EP09820929A EP09820929A EP2276502A4 EP 2276502 A4 EP2276502 A4 EP 2276502A4 EP 09820929 A EP09820929 A EP 09820929A EP 09820929 A EP09820929 A EP 09820929A EP 2276502 A4 EP2276502 A4 EP 2276502A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- neuroinjury
- prevention
- compositions
- treatment
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7190108P | 2008-05-23 | 2008-05-23 | |
PCT/US2009/045019 WO2010044917A1 (en) | 2009-05-22 | 2009-05-22 | Compositions for the prevention and treatment of neuroinjury and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2276502A1 EP2276502A1 (en) | 2011-01-26 |
EP2276502A4 true EP2276502A4 (en) | 2012-04-04 |
Family
ID=43384474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09820929A Withdrawn EP2276502A4 (en) | 2008-05-23 | 2009-05-22 | Compositions for the prevention and treatment of neuroinjury and methods of use thereof |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2276502A4 (en) |
AU (1) | AU2009303786B2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999018976A1 (en) * | 1997-10-14 | 1999-04-22 | Cambridge Neuroscience, Inc. | Therapeutic methods comprising use of a neuregulin |
WO2006017184A2 (en) * | 2004-07-09 | 2006-02-16 | Wayne State University | HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING |
US20070155665A1 (en) * | 2005-09-02 | 2007-07-05 | Byron Ford | Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration |
-
2009
- 2009-05-22 EP EP09820929A patent/EP2276502A4/en not_active Withdrawn
- 2009-05-22 AU AU2009303786A patent/AU2009303786B2/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999018976A1 (en) * | 1997-10-14 | 1999-04-22 | Cambridge Neuroscience, Inc. | Therapeutic methods comprising use of a neuregulin |
WO2006017184A2 (en) * | 2004-07-09 | 2006-02-16 | Wayne State University | HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING |
US20070155665A1 (en) * | 2005-09-02 | 2007-07-05 | Byron Ford | Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration |
Non-Patent Citations (2)
Title |
---|
See also references of WO2010044917A1 * |
XU Z ET AL: "Neuregulin-1 is neuroprotective and attenuates inflammatory responses induced by ischemic stroke", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 322, no. 2, 17 September 2004 (2004-09-17), pages 440 - 446, XP004527639, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2004.07.149 * |
Also Published As
Publication number | Publication date |
---|---|
AU2009303786B2 (en) | 2014-06-05 |
EP2276502A1 (en) | 2011-01-26 |
AU2009303786A1 (en) | 2010-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190059T1 (en) | Compositions for the treatment of pain and/or inflammation | |
HK1250392A1 (en) | Methods and compositions for the detection and treatment of preeclampsia | |
EP2361089A4 (en) | Compositions and methods for the treatment of altered -synuclein function | |
HK1207594A1 (en) | Compositions and methods for the prevention and treatment of autoimmune conditions | |
PL3208612T3 (en) | Compositions and methods for the treatment of immune related diseases | |
HRP20160902T1 (en) | Compositions and methods of use of phorbolesters | |
HK1159498A1 (en) | Methods and compositions for the treatment of cancer | |
EP2212440A4 (en) | Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas | |
EP2331123A4 (en) | Compositions and methods for the treatment of hepatitis c | |
IL210997A0 (en) | Compositions for the treatment of mrsa and uses thereof | |
GB0718446D0 (en) | Compositions and methods for the treatment of infection | |
HK1166305A1 (en) | Compositions and methods for the treatment of inflammation | |
EP2340027A4 (en) | Methods and compositions for the treatment of cancer | |
IL196843A0 (en) | Compositions and methods for the treatment of radiation proctosigmoitis | |
EP2249789A4 (en) | Compositions and methods for the treatment of xerostomia | |
HUE044621T2 (en) | Compounds and methods for the prevention or treatment of restenosis | |
EP2150270A4 (en) | Methods and compositions for the treatment of cancer | |
EP2142566A4 (en) | Methods and compositions for the treatment of proliferative diseases | |
EP2285398A4 (en) | Methods and compositions for the treatment of obesity | |
EP2480099A4 (en) | Compositions and methods for the prevention and treatment of metabolic diseases | |
EP2370087A4 (en) | Methods and compositions for the treatment of fluid retention disorders | |
EP2274042A4 (en) | Treatment and/or prevention of multiple sclerosis | |
GB0808326D0 (en) | Compositions and methods for the treatment of fybromyalgia | |
GB0808730D0 (en) | Compositions and methods for the prevention and treatment of schistosomiasis | |
EP2276502A4 (en) | Compositions for the prevention and treatment of neuroinjury and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100430 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120301 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/28 20060101ALI20120224BHEP Ipc: A61K 38/18 20060101AFI20120224BHEP |
|
17Q | First examination report despatched |
Effective date: 20130228 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20140422 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140903 |